Edition:
United States

Korian SA (KORI.PA)

KORI.PA on Paris Stock Exchange

30.09EUR
4:02am EST
Change (% chg)

€-0.50 (-1.65%)
Prev Close
€30.59
Open
€30.59
Day's High
€30.60
Day's Low
€30.06
Volume
22,074
Avg. Vol
103,393
52-wk High
€32.13
52-wk Low
€25.00

Chart for

About

Korian SA, formerly Korian Medica SA, is a France-based company that operates healthcare facilities and medical establishments. The Company's holdings include residential centers for the elderly (EHPAD), offering permanent social care and medical support; follow-up care and rehabilitation centers, including general and... (more)

Overall

Beta: 0.59
Market Cap(Mil.): €2,477.66
Shares Outstanding(Mil.): 80.98
Dividend: 0.60
Yield (%): 1.96

Financials

  Industry Sector
P/E (TTM): -- 29.20 15.25
EPS (TTM): -- -- --
ROI: -- 8.04 33.27
ROE: -- 11.76 16.35

BRIEF-Korian Q3 revenue up at 791 million euros

* Q3 REVENUE EUR 791 ‍MILLION VERSUS EUR 754 MILLION YEAR AGO

Oct 24 2017

BRIEF-Korian H1 net profit group share rises to 38 million euros

* H1 EBITDA EUR 209 MILLION VERSUS EUR 206.7 MILLION YEAR AGO

Sep 13 2017

BRIEF-Icade announces that Korian Group, Icade Santé and Icade Promotion signed a development partnership

* KORIAN GROUP, ICADE SANTÉ AND ICADE PROMOTION SIGNED A DEVELOPMENT PARTNERSHIP

Sep 13 2017

BRIEF-Korian to distribute a dividend of 0.60 euros per share for FY 2016

* WILL PROCEED ON JULY 21 TO DISTRIBUTE A DIVIDEND OF € 0.60 PER SHARE FOR THE YEAR ENDED DECEMBER 31, 2016 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jul 19 2017

BRIEF-Korian Q2 revenue rises by 5.1 percent

* KORIAN MEDICA SA - KORIAN ANNOUNCES REVENUE UP 5.1% IN SECOND QUARTER 2017

Jul 19 2017

BRIEF-Korian announces final terms of bond issue

* ANNOUNCES ITS FINAL TERMS OF UNSUBORDINATED UNDATED BONDS CONVERTIBLE INTO NEW SHARES AND/OR EXCHANGEABLE FOR EXISTING SHARES (ODIRNANE) FOR ABOUT € 240 MILLION

Jun 28 2017

BRIEF-French group Korian announces bond issues

* Korian launches an offering of unsubordinated undated bonds convertible into new shares and/or exchangeable for existing shares (ODIRNANE) for an amount of approximately €200 million

Jun 28 2017

Earnings vs. Estimates